drugset / Trial / NCT00699062

Effect of Montelukast on the Airway Remodeling

NCT00699062

Phase 4 Completed 40 enrolled Chinese Academy of Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

The distal lung contributes to asthmatic airway remodeling which is observed from early onset of the disease. Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory effect. The cysteinyl leukotriene antagonist Montelukast has been in vivo shown to significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial fibrosis in sensitized mice. This study aims to evaluate if Montelukast could reverse airway remodeling in asthma patients by a non-invasive approach-HRCT.

Timeline

Start
2010-01
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 10 mg Oral

Indications